-+ 0.00%
-+ 0.00%
-+ 0.00%

Celldex halts barzolvolimab development in atopic dermatitis after Phase 2 trial misses key endpoints

PUBT·11/19/2026 21:02:32
Listen to the news
Celldex halts barzolvolimab development in atopic dermatitis after Phase 2 trial misses key endpoints
  • Celldex discontinued barzolvolimab development in atopic dermatitis following newly reported Phase 2 results that missed key efficacy goals.
  • Treatment benefits fell short of internal development requirements, despite a favorable safety profile.
  • A biologics license application for chronic spontaneous urticaria remains planned for 2027; Phase 3 trials in other urticaria indications are enrolling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611191601PRIMZONEFULLFEED9881725) on November 19, 2026, and is solely responsible for the information contained therein.